Sign in
Not yet recruitingPhase 3

Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia

Key facts

Who runs it
McGill University Health Centre/Research Institute of the McGill University Health Centre
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
416 people, planned
Starts
1 Apr 2027
Expected to end
31 Dec 2032
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Echinocandins
  • Placebo (0.9% Sodium chloride) infusion
Record updated
5 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Immunocompromised adults (≥18 years old) in an emergency department or hospital with a proven or probable diagnosis of PCP
  • Severe PCP, defined as proven or probable PCP with new or increased PCP-attributable hypoxemic respiratory failure meeting at least one of the following criteria: a requirement for ≥4 L/min supplemental oxygen by nasal cannula to maintain oxygenation >94%; a requirement for FiO₂ ≥0.35 via a controlled oxygen-delivery device; or a requirement for advanced respiratory support, including invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). For patients with chronic baseline oxygen use, the increased support must be attributable to PCP
  • Currently receiving, or eligible to receive, systemic anti-PCP therapy for the current episode. Patients receiving empiric PCP treatment may be enrolled before microbiological or pathological results are available if results are expected within 1 week
  • No later than 48 hours after screening for inclusion and before more than 3 days of PCP therapy have elapsed
  • Provision of informed consent by the participant or substitute decision maker, as locally applicable; Clinical Exclusion Criteria
  • More than 3 days of effective anti-PCP therapy before enrolment in ECHINO-PCP
  • Another infection or clinical indication that independently requires echinocandin therapy
  • Known allergy or hypersensitivity to echinocandins
  • Receipt of more than 24 hours of caspofungin, micafungin, or anidulafungin, or receipt of one dose of rezafungin, before enrolment
  • PCP is no longer considered the most likely diagnosis at the time of randomization
  • PCP therapy has already been escalated or changed for presumed treatment failure before enrolment
  • Death is deemed imminent (<48 hours), as determined by the treating team and site investigator
  • Treatment with antifungals is inconsistent with the patient's advanced care directives; Administrative Exclusion Criteria
  • Inability to obtain informed consent, or refusal to consent by the patient or substitute decision maker
  • Treating team declines participation
  • Inability to ensure reliable follow-up (e.g., lack of means of communication or patient non-resident of the jurisdiction)
  • Prior enrolment in ECHINO-PCP

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Preclinical studies and retrospective clinical data suggest that adjunctive echinocandin therapy may improve outcomes in adults with severe Pneumocystis jirovecii pneumonia (PCP). However, the benefit of adding an echinocandin to standard PCP treatment has not been established in a definitive randomized controlled trial. The aim of this trial is:

Read full original descriptionShow less

1. In adults hospitalized with severe PCP, to determine whether adding an echinocandin to standard anti-PCP therapy improves net clinical outcomes by Day 30 compared with standard anti-PCP therapy plus matching placebo.

The 2 groups in the trial

  • EchinocandinTreatment being tested

    Echinocandin IV + standard anti-PCP therapy until discharge or 7 days, whichever occurs first.

    Treatment: Echinocandins

  • PlaceboPlacebo, for comparison

    0.9% sodium chloride IV placebo + standard anti-PCP therapy until discharge or 7 days, whichever occurs first.

    Treatment: Placebo (0.9% Sodium chloride) infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjunctive Echinocandin for Severe Pneumocystis Jirovecii Pneumonia (ECHINO-PCP)
Record updated
5 November 2026